Skip to main content
Premium Trial:

Request an Annual Quote

Genelex CLIA DNA Test Approved by New York

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Genelex today said that New York state has approved its CLIA-based DNA Drug Sensitivity Tests for the testing of three enzymes involved in drug metabolism.

The approval means Genelex's CLIA lab has regulatory approval to test patient samples from every state in the US, "a critical milestone for Genelex," the company said in a statement.

The test is for three enzymes, the cytochrome P450s, which process more than half of the most commonly prescribed medicines. According to Genelex, research indicates that most patients have one or more defects in the genetic coding of these enzymes, increasing the chances of adverse, sometimes life-threatening, side effects, or non-response to the therapies.

In a statement, Howard Coleman, CEO of Seattle-based Genelex, said the approval by the New York State Department of Health has particular implications for patients who do not respond to the anti-coagulant drug Plavix, generically known as clopidogrel. The company's test for Plavix response, the Plavistest DNA test, identifies these patients, "allowing doctors to personalized treatments and reduce the risks of recurrent heart attack, stroke, or cardiovascular risks," Coleman said.

Earlier this year, the US Food and Drug Administration issued a black box warning on Plavix's label saying that some patients may have diminished function of the CYP2C19 enzyme, resulting in poor metabolism of the drug. The agency further said that doctors may consider genetically testing a patient for this before prescribing Plavix or consider other treatments.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.